Results 31 to 40 of about 573,829 (353)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma

Frontiers in Oncology, 2021
Combination immunotherapy can overcome the limited objective response rates of PD-1 blockade. Interferon alpha (IFN-α) has been proven to be effective in modulating immune responses and may enhance the clinical responses to PD-1 blockade.
Dong-Dong Jia, Yanling Niu, Honglin Zhu, Sizhen Wang, Tonghui Ma, Tao Li   +5 more
doaj   +1 more source

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer [PDF]

, 2015
Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours ...
Biglia, Nicoletta, CODACCI PISANELLI, Giovanni, Colombo, Nicoletta, Cont, Nicoletta Tomasi, D'Alonzo, Marta, Ferrero, Annamaria, Peccatori, Fedro Alessandro   +6 more
core   +7 more sources

Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers [PDF]

Zhongguo aizheng zazhi, 2022
Background and purpose: Anti-programmed death-1 (anti-PD-1) adjuvant therapy and targeted therapy have resulted in longer recurrence-free survival (RFS) for malignant melanoma patients in clinical trials.
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong
doaj   +1 more source

Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature [PDF]

, 2018
Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma that is treated with first-line therapy, using surgical resection followed by local radiotherapy and concomitant/adjuvant temozolomide (TMZ) treatment.
Berrios J. R. G., Bianco V., Caffarena G., Caporlingua A., Caporlingua F., Di Palma A., Fusto C., Magliocca F. M., Pecorari S., Prelaj A., Rebuzzi S. E., Salvati M., Tomao S.   +12 more
core   +1 more source

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

BMC Cancer, 2023
Purpose To determine the role and rational application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant non-small-cell lung cancer (NSCLC).
Shu-Ling Zhang, Xiao-Fang Yi, Le-Tian Huang, Li Sun, Jie-Tao Ma, Cheng-Bo Han   +5 more
doaj   +1 more source

Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion

Current Oncology, 2023
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. Some patients with HCC are diagnosed with macrovascular invasion (MVI), which is associated with a poorer prognosis.
Che-Jui Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Cheng-Yuan Peng   +7 more
doaj   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer. Efficacy in combination with hormonal therapy [PDF]

, 2012
Background: Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no ...
Cognetti F., D'Auria G., De Vita F., Fabi A., Ferretti G., Giannarelli D., Metro G., Nistico C., Papaldo P., Russillo M., Vidiri A.   +10 more
core   +3 more sources

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. [PDF]

, 2017
PurposeTumor levels of thymidylate synthase (TS), a target of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer, have been studied as a predictive or prognostic biomarker with mixed results.Patients and methodsTumor TS levels were ...
Bertagnolli, Monica M, Colacchio, Thomas A, Compton, Carolyn C, Fuchs, Charles S, Goldberg, Richard M, Hasson, Rian M, Lenz, Heinz-Josef, Mayer, Robert J, Niedzwiecki, Donna, Ogino, Shuji, Redston, Mark, Saltz, Leonard B, Warren, Robert S, Ye, Cynthia   +13 more
core   +1 more source

Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer

Radiology and Oncology, 2019
The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy.
Ovcaricek Tanja, Takac Iztok, Matos Erika   +2 more
doaj   +1 more source